+

WO2004023973A3 - Molecules for diagnostics and therapeutics - Google Patents

Molecules for diagnostics and therapeutics Download PDF

Info

Publication number
WO2004023973A3
WO2004023973A3 PCT/US2003/028227 US0328227W WO2004023973A3 WO 2004023973 A3 WO2004023973 A3 WO 2004023973A3 US 0328227 W US0328227 W US 0328227W WO 2004023973 A3 WO2004023973 A3 WO 2004023973A3
Authority
WO
WIPO (PCT)
Prior art keywords
dithp
provides
therapeutics
diagnostics
diagnostic assays
Prior art date
Application number
PCT/US2003/028227
Other languages
French (fr)
Other versions
WO2004023973A2 (en
Inventor
Jeanette P Schmidt
Rachel J Wright
Christopher M Bruns
Mirjana M Marjanovic
Fan Shen
Toinette A Harthshorne
Martin T Suchorolski
Christina M Altus
Steven J Pitts
Linda V Elder
Original Assignee
Incyte Corp
Jeanette P Schmidt
Rachel J Wright
Christopher M Bruns
Mirjana M Marjanovic
Fan Shen
Toinette A Harthshorne
Martin T Suchorolski
Christina M Altus
Steven J Pitts
Linda V Elder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp, Jeanette P Schmidt, Rachel J Wright, Christopher M Bruns, Mirjana M Marjanovic, Fan Shen, Toinette A Harthshorne, Martin T Suchorolski, Christina M Altus, Steven J Pitts, Linda V Elder filed Critical Incyte Corp
Priority to AU2003289716A priority Critical patent/AU2003289716A1/en
Publication of WO2004023973A2 publication Critical patent/WO2004023973A2/en
Publication of WO2004023973A3 publication Critical patent/WO2004023973A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention provides purified human polynucleotides for diagnostics and therapeutics (dithp). Also encompassed are the polypeptides (DITHP) encoded by dithp. The invention also provides for the use of dithp, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing ditph for the expression of DITHP. The invention additionally provides for the use of isolated and purified DITHP to induce antibodies and to screen libraries of compounds and the use of anti-DITHP antibodies in diagnostic assays. Also provided are microarrays containing dithp and methods of use.
PCT/US2003/028227 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics WO2004023973A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003289716A AU2003289716A1 (en) 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41025902P 2002-09-12 2002-09-12
US41026002P 2002-09-12 2002-09-12
US60/410,260 2002-09-12
US60/410,259 2002-09-12

Publications (2)

Publication Number Publication Date
WO2004023973A2 WO2004023973A2 (en) 2004-03-25
WO2004023973A3 true WO2004023973A3 (en) 2004-09-23

Family

ID=31997928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/028227 WO2004023973A2 (en) 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics

Country Status (2)

Country Link
AU (1) AU2003289716A1 (en)
WO (1) WO2004023973A2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168180B2 (en) 2002-11-27 2012-05-01 Technion Research & Development Foundation Ltd. Methods and compositions for modulating angiogenesis
US8461303B2 (en) 2007-08-02 2013-06-11 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9127268B2 (en) 2009-12-11 2015-09-08 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
CN105111311A (en) * 2005-12-20 2015-12-02 Sbi生物技术有限公司 Anti-ILT7-antibody
US9273302B2 (en) 2012-02-16 2016-03-01 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9284609B2 (en) 2005-09-12 2016-03-15 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US9340780B2 (en) 2010-05-03 2016-05-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9428743B2 (en) 2010-08-25 2016-08-30 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003054141A2 (en) * 2001-10-22 2003-07-03 Children's Medical Center Corporation Sperm-specific cation channel, catsper2, and uses therefor
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
EP1581641A4 (en) * 2002-12-06 2006-11-15 Diadexus Inc Compositions, splice variants and methods relating to ovarian specific genes and proteins
US8871709B2 (en) * 2003-02-05 2014-10-28 Queensland University of Technolgy Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
EP1615991A4 (en) 2003-04-03 2007-12-19 Bristol Myers Squibb Co Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v
WO2004094623A2 (en) * 2003-04-04 2004-11-04 Incyte Corporation Cell adhesion and extracellular matrix proteins
AU2004238703B2 (en) * 2003-05-14 2008-07-24 Sumitomo Chemical Company, Limited Liver X receptor alpha splicing mutant protein, gene thereof and utilization of the same
EP1697413A2 (en) * 2003-08-18 2006-09-06 Wyeth Human lxr alpha variants
DK1694342T3 (en) * 2003-11-12 2021-02-08 Univ Pennsylvania PROCEDURES FOR THE USE OF GELSOLIN FOR THE TREATMENT OR PREVENTION OF BACTERIAL SEPSIS
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
ATE510020T1 (en) * 2003-12-24 2011-06-15 G2 Inflammation Pty Ltd TRANSGENIC NON-HUMAN MAMMAL WITH A POLYNUCLEOTIDE CODING FOR HUMAN-C5AR OR HUMANIZED C5AR
WO2005076012A2 (en) * 2004-01-30 2005-08-18 Five Prime Therapeutics, Inc. Novel splice variants and methods of use thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
KR101300929B1 (en) 2004-05-12 2013-08-27 더 브리검 앤드 우먼즈 하스피털, 인크. Use of gelsolin to treat infections
EP1794314A2 (en) * 2004-07-23 2007-06-13 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
WO2006008008A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a)
AU2005299089B2 (en) * 2004-10-21 2011-08-18 Eberhard Karls Universitaet Tuebingen KASPP (LRKK2) gene, its production and use for the detection and treatment of neurodegenerative disorders
JP2008522632A (en) 2004-12-13 2008-07-03 アレシア・バイオセラピューティクス・インコーポレーテッド Polynucleotide and polypeptide sequences involved in the process of bone remodeling
KR100664587B1 (en) * 2004-12-22 2007-01-04 김현기 Human cancer suppressor gene, protein encoded thereby, expression vector comprising the same and cells transformed with the vector
EP1891234B1 (en) 2005-06-01 2014-12-10 Evotec International GmbH Use of slc39a12 proteins as target in diagnosis and drug screening in alzheimer's disease
EP1739092A1 (en) * 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidic antagonists of class III semaphorins/neuropilins complexes
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
AU2014265023A1 (en) * 2005-12-20 2014-12-04 Sbi Biotech Co, Ltd. Anti-ILT7 Antibody
AU2012244391B2 (en) * 2005-12-20 2014-09-11 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
DK1973946T3 (en) * 2006-01-20 2015-06-22 Cell Signaling Technology Inc TRANSLOCATION AND MUTANT ROSE KINASE IN HUMAN NON-SMALL CELL LUNGCARCINOM
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
US20070192885A1 (en) * 2006-01-26 2007-08-16 Daniel Chelsky TAT-039 and methods of assessing and treating cancer
WO2007089783A2 (en) * 2006-01-30 2007-08-09 Caprion Pharmaceuticals, Inc. Tat-044 and methods of assessing and treating cancer
WO2007089793A2 (en) * 2006-01-31 2007-08-09 Caprion Pharmaceuticals, Inc. Tat-041 and methods of assessing and treating cancer
CN101460843B (en) 2006-03-15 2018-06-22 布赖汉姆妇女医院有限公司 The purposes of gelsolin to treat multiple sclerosis and diagnosis neurological disease
WO2007109056A2 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
US7452985B2 (en) 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
US9513296B2 (en) 2006-08-21 2016-12-06 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US9689879B2 (en) 2006-08-21 2017-06-27 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
WO2008042814A2 (en) * 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
CA2668800A1 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
JP5580205B2 (en) 2007-11-19 2014-08-27 セレラ コーポレーション Lung cancer markers and their use
JP2011509652A (en) * 2008-01-07 2011-03-31 パトリス・リミテッド BARB4 target comprising TATA-binding protein associated factor 15, an antibody called BARB4, a BARB4-related antibody, and methods of making and using them
DK2250280T3 (en) 2008-01-25 2015-03-09 Gen Hospital Corp THERAPEUTIC USES OF gelsolin in renal failure
US8557575B2 (en) 2008-01-28 2013-10-15 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
EP2322610B1 (en) 2008-07-16 2016-12-14 Medical and Biological Laboratories Co., Ltd. Anti-human clcp1 antibody and use thereof
AU2013202419B2 (en) * 2008-07-16 2014-11-27 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and uses thereof
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
WO2010033294A1 (en) * 2008-09-22 2010-03-25 Cedars-Sinai Medical Center Short-form human md-2 as a negative regulator of toll-like receptor 4 signaling
EP3032258B1 (en) * 2008-12-30 2021-05-12 Children's Medical Center Corporation Method of predicting acute appendicitis
EP3255146B1 (en) 2009-03-16 2019-05-15 Pangu Biopharma Limited Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
JP4495776B1 (en) * 2009-07-30 2010-07-07 日本製薬株式会社 Fusion protein
CA2774349C (en) 2009-09-17 2019-03-19 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
RU2563359C2 (en) 2009-11-30 2015-09-20 Дженентек, Инк. Compositions and methods for diagnostics and treatment of tumour
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
MX339621B (en) 2010-04-13 2016-06-02 Celldex Therapeutics Inc * Antibodies that bind human cd27 and uses thereof.
WO2012042038A2 (en) * 2010-09-30 2012-04-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Chimeric peptides including a penetrating peptide and a binding domain of pp2a catalytic subunit to caspase-9
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
EP2771689A4 (en) * 2011-10-26 2015-06-03 Nuclea Biotechnologies Inc Usp2a peptides and antibodies
CN104271593B (en) 2012-05-01 2018-01-16 富士胶片株式会社 The polypeptide used in the cultural method and this method of multipotential stem cell
ES2966030T3 (en) * 2012-10-05 2024-04-18 Kadmon Corp Llc Human anti-VEGFR-2/KDR antibodies
BR112015021399A2 (en) 2013-03-14 2017-07-18 Bayer Healthcare Llc heparin-complexed antithrombin beta monoclonal antibodies
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
CN107771285A (en) 2015-06-08 2018-03-06 阿奎尔诊断有限公司 Method
WO2017024137A1 (en) * 2015-08-04 2017-02-09 New York University Progranulin (pgrn) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
KR102603010B1 (en) 2016-03-10 2023-11-16 비엘라 바이오, 인크. Ilt7 binding molecules and methods of using the same
SMT202200306T1 (en) 2016-04-08 2022-09-14 Immunocore Ltd T cell receptors
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
AU2018266705B2 (en) 2017-05-08 2023-05-04 Gritstone Bio, Inc. Alphavirus neoantigen vectors
KR102760654B1 (en) 2017-06-07 2025-02-04 리제너론 파마슈티칼스 인코포레이티드 Compositions and methods for enzyme internalization
TW202428875A (en) * 2017-07-31 2024-07-16 香港商映像生物有限公司 Nucleic acid molecules for targeting the cyp4v2 gene and treating bietti crystalline dystrophy
IL315325A (en) 2018-01-04 2024-10-01 Iconic Therapeutics Inc Anti-tissue-mediated antibodies, antibody-drug conjugates, and related methods
MA51796A (en) 2018-02-07 2020-12-16 Regeneron Pharma METHODS AND COMPOSITIONS FOR THE ADMINISTRATION OF THERAPEUTIC PROTEINS
GB201803010D0 (en) * 2018-02-26 2018-04-11 Royal Holloway & Bedford New College Neurodegenerative disorders
SG11202010011RA (en) 2018-04-17 2020-11-27 Celldex Therapeutics Inc Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
SG11202011232VA (en) 2018-05-17 2020-12-30 Regeneron Pharma Anti-cd63 antibodies, conjugates, and uses thereof
AU2020282369A1 (en) 2019-05-30 2022-01-20 Gritstone Bio, Inc. Modified adenoviruses
CN111859913B (en) * 2020-06-12 2024-04-12 北京百度网讯科技有限公司 Processing method and device of wind control characteristic factors, electronic equipment and storage medium
AU2021320896A1 (en) 2020-08-06 2023-03-23 Gritstone Bio, Inc. Multiepitope vaccine cassettes
US20240092859A1 (en) 2022-08-18 2024-03-21 Immunocore Ltd T cell receptors and fusion proteins thereof
WO2024163607A2 (en) * 2023-02-02 2024-08-08 Board Of Regents, The University Of Texas System T-cell receptors targeting egfr and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053531A2 (en) * 2000-01-18 2001-07-26 Pharmacia Corporation Osteoarthritis tissue derived nucleic acids, polypeptides, vectors, and cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053531A2 (en) * 2000-01-18 2001-07-26 Pharmacia Corporation Osteoarthritis tissue derived nucleic acids, polypeptides, vectors, and cells

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168180B2 (en) 2002-11-27 2012-05-01 Technion Research & Development Foundation Ltd. Methods and compositions for modulating angiogenesis
US9284609B2 (en) 2005-09-12 2016-03-15 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
CN105111311B (en) * 2005-12-20 2019-10-18 Sbi生物技术有限公司 anti-ILT7 antibody
CN105111311A (en) * 2005-12-20 2015-12-02 Sbi生物技术有限公司 Anti-ILT7-antibody
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US8461303B2 (en) 2007-08-02 2013-06-11 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US8679485B2 (en) 2007-08-02 2014-03-25 Gilead Biologics, Inc. Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US9176139B2 (en) 2007-08-02 2015-11-03 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9289447B2 (en) 2009-01-06 2016-03-22 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US9328340B2 (en) 2009-12-11 2016-05-03 Atyr Pharma, Inc. Amino acyl tRNA synthetases for modulating inflammation
US9540628B2 (en) 2009-12-11 2017-01-10 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US9127268B2 (en) 2009-12-11 2015-09-08 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US9340780B2 (en) 2010-05-03 2016-05-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9428743B2 (en) 2010-08-25 2016-08-30 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
US9273302B2 (en) 2012-02-16 2016-03-01 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates

Also Published As

Publication number Publication date
WO2004023973A2 (en) 2004-03-25
AU2003289716A1 (en) 2004-04-30
AU2003289716A8 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
WO2004023973A3 (en) Molecules for diagnostics and therapeutics
WO2002097031A3 (en) Molecules for diagnostics and therapeutics
WO2000073509A3 (en) Molecules for diagnostics and therapeutics
WO2002083876A3 (en) Secretory molecules
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
WO2007054520A3 (en) Methods for the identification of microrna and their applications in research and human health
WO2006056480A3 (en) Means and methods for detecting methylated dna
WO2002046228A3 (en) Receptor for b. anthracis toxin
WO2003020894A3 (en) Insulin related transcription factor and uses thereof
WO2003062376A3 (en) Molecules for diagnostics and therapeutics
WO2002040715A8 (en) Molecules for disease detection and treatment
WO2002020756A3 (en) Secretory molecules
WO2002078526A3 (en) Cancer-testis antigens
WO2001062927A3 (en) Polypeptides and corresponding polynucleotides for diagnostics and therapeutics
WO2008124170A3 (en) SELECTION OF HUMAN TNFα SPECIFIC ANTIBODIES
WO2003062385A3 (en) Secretory molecules
WO2004066933A3 (en) Compositions and methods for treating cancer using igsf9 and liv-1
WO2001062922A3 (en) Polypeptides and corresponding molecules for disease detection and treatment
WO2002020754A3 (en) Molecules for diagnostics and therapeutics
WO2005069854A3 (en) Methods and materials relating to novel c1q domain-containing polypeptides and polynucleotides
WO2002055738A3 (en) Molecules for disease detection and treatment
WO2001062918A3 (en) Secretory polypeptides and corresponding polynucleotides
WO2002079473A3 (en) Molecules for diagnostics and therapeutics
WO2001021836A3 (en) Molecules for diagnostics and therapeutics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载